Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a collaboration and license agreement with Novartis AG, and are currently running a phase IB/II trial, RED4MS, with the lead product CLS12311.
- http://www.cellerys.com
- info@cellerys.com
- Nicholas Barbet, COO
